Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY OLE
NCT01954394Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2013
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Sanofi. Started Dec 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01954394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01954394.